Cellply srl has obtained a grant by the European Commission to support its R&D program
Maggio 2018 — Cellply has obtained a grant by the European Commission to support its R&D program. It is the largest one among the nine Italian companies funded in the last SME Instrument call and one of the largest at EU level since the start of the SME Instrument program in 2014. This will provide the resources to complete the development of an innovative diagnostic platform.
Cellply, based in Bologna, Italy, was founded in 2013 by two engineers, Professor Roberto Guerrieri from the University of Bologna and Massimo Bocchi. It is a medtech start-up company specialized in in vitro diagnostic systems aiming at supporting personalized oncology treatments. In 2014, the company started the development of an in vitro diagnostic platform which enabled the isolation of a tiny amount of live tumor cells sampled from patients within 20,000 microwells and to analyze the action of multiple drugs in parallel by means of proprietary algorithms to predict the response of the patient to candidate drug therapies.
Il nostro ruolo nella transazione
Oaklins' team in Italy successfully assisted Cellply along the entire fundraising process.
Discuti con...
Giuseppe Maria Bernardo Puccio
Oaklins Italy
Deal relazionato
UKAT Group has acquired Bayberry Limited
UK Addiction Treatment (UKAT) Group, a leading UK provider of residential addiction, mental health and behavioral health treatment backed by Sullivan Street Partners, has acquired Bayberry Limited, a specialist mental health and wellbeing treatment provider. Joining UKAT enables Bayberry to preserve continuity of care for patients and referral partners, retain the strength of its clinical team and benefit from UKAT’s operational infrastructure, referral network and marketing channels. This partnership supports Bayberry’s next stage of development while preserving the qualities that differentiate its service offering.
Per saperne di piùMedicija has acquired Saulės Šeimos Medicinos Centras
Medicija has acquired a 100% stake in Saulės Šeimos Medicinos Centras.
Per saperne di piùQuimpharma has completed the divestiture of a product portfolio to Megalabs
Quimpharma has completed the divestiture of a product portfolio to Megalabs México.
Per saperne di più